Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?

doi:10.1001/jama.2018.4863

. 2018 Jun 19;319(23):2379-2380.

doi: 10.1001/jama.2018.4863.

Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?

Kathryn A Phillips^{1

2

3

4}

Affiliations

¹ Department of Clinical Pharmacy, University of California, San Francisco.
² Center for Translational and Policy Research on Personalized Medicine, San Francisco, California.
³ Philip R. Lee Institute for Health Policy, University of California, San Francisco.
⁴ Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.

PMID: 29710095
PMCID: PMC6013401
DOI: 10.1001/jama.2018.4863

Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?

Kathryn A Phillips. JAMA. 2018.

. 2018 Jun 19;319(23):2379-2380.

doi: 10.1001/jama.2018.4863.

Author

Kathryn A Phillips^{1

2

3

4}

Affiliations

¹ Department of Clinical Pharmacy, University of California, San Francisco.
² Center for Translational and Policy Research on Personalized Medicine, San Francisco, California.
³ Philip R. Lee Institute for Health Policy, University of California, San Francisco.
⁴ Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.

PMID: 29710095
PMCID: PMC6013401
DOI: 10.1001/jama.2018.4863

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Phillips reported receiving personal fees from Illumina and Counsyl.

Cited by

Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy.
Trosman JR, Weldon CB, Kurian AW, Pasquinelli MM, Kircher SM, Martin N, Douglas MP, Phillips KA. Trosman JR, et al. Health Aff Sch. 2023 Jun 20;1(1):qxad005. doi: 10.1093/haschl/qxad005. eCollection 2023 Jul. Health Aff Sch. 2023. PMID: 38756840 Free PMC article.
A randomized controlled trial of analogue pharmacogenomic testing feedback for psychotropic medications.
Young J, Jimenez A, Pruett M, Hancock L, Schruff M. Young J, et al. PEC Innov. 2022 Dec 16;2:100119. doi: 10.1016/j.pecinn.2022.100119. eCollection 2023 Dec. PEC Innov. 2022. PMID: 37214496 Free PMC article.
Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured.
Epstein RL, Wang J, White LF, Kapadia SN, Morgan JR, Bao Y, Linas BP. Epstein RL, et al. Am J Prev Med. 2022 Sep;63(3):e87-e98. doi: 10.1016/j.amepre.2022.03.010. Epub 2022 Jun 18. Am J Prev Med. 2022. PMID: 35725599 Free PMC article.
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.
Koleva-Kolarova R, Buchanan J, Vellekoop H, Huygens S, Versteegh M, Mölken MR, Szilberhorn L, Zelei T, Nagy B, Wordsworth S, Tsiachristas A; HEcoPerMed Consortium. Koleva-Kolarova R, et al. Appl Health Econ Health Policy. 2022 Jul;20(4):501-524. doi: 10.1007/s40258-021-00714-9. Epub 2022 Apr 4. Appl Health Econ Health Policy. 2022. PMID: 35368231 Free PMC article.
The Role of Medical Mistrust in Concerns about Tumor Genomic Profiling among Black and African American Cancer Patients.
Hoadley A, Bass SB, Chertock Y, Brajuha J, D'Avanzo P, Kelly PJ, Hall MJ. Hoadley A, et al. Int J Environ Res Public Health. 2022 Feb 23;19(5):2598. doi: 10.3390/ijerph19052598. Int J Environ Res Public Health. 2022. PMID: 35270290 Free PMC article.

See all "Cited by" articles

References

1. Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood) 2014;33(7):1246–1253. - PMC - PubMed
1. US Centers for Medicare & Medicaid Services. [Accessed March 16, 2018];Decision memo for next generation sequencing for Medicare beneficiaries with advanced cancer. https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo....
1. Phillips KA, Deverka PA, Trosman JR, et al. Payer coverage policies for multigene tests. Nat Biotechnol. 2017;35(7):614–617. - PMC - PubMed
1. Levinson D. [Accessed March 19, 2018];Local coverage determinations create inconsistency in Medicare coverage. https://oig.hhs.gov/oei/reports/oei-01-11-00500.pdf.
1. Trosman JR, Weldon CB, Douglas MP, et al. Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the precision medicine initiative. J Natl Compr Canc Netw. 2017;15(2):219–228. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood) 2014;33(7):1246–1253. - PMC - PubMed

[2] Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood) 2014;33(7):1246–1253. - PMC - PubMed

[3] US Centers for Medicare & Medicaid Services. [Accessed March 16, 2018];Decision memo for next generation sequencing for Medicare beneficiaries with advanced cancer. https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo....

[4] US Centers for Medicare & Medicaid Services. [Accessed March 16, 2018];Decision memo for next generation sequencing for Medicare beneficiaries with advanced cancer. https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo....

[5] Phillips KA, Deverka PA, Trosman JR, et al. Payer coverage policies for multigene tests. Nat Biotechnol. 2017;35(7):614–617. - PMC - PubMed

[6] Phillips KA, Deverka PA, Trosman JR, et al. Payer coverage policies for multigene tests. Nat Biotechnol. 2017;35(7):614–617. - PMC - PubMed

[7] Levinson D. [Accessed March 19, 2018];Local coverage determinations create inconsistency in Medicare coverage. https://oig.hhs.gov/oei/reports/oei-01-11-00500.pdf.

[8] Levinson D. [Accessed March 19, 2018];Local coverage determinations create inconsistency in Medicare coverage. https://oig.hhs.gov/oei/reports/oei-01-11-00500.pdf.

[9] Trosman JR, Weldon CB, Douglas MP, et al. Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the precision medicine initiative. J Natl Compr Canc Netw. 2017;15(2):219–228. - PMC - PubMed

[10] Trosman JR, Weldon CB, Douglas MP, et al. Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the precision medicine initiative. J Natl Compr Canc Netw. 2017;15(2):219–228. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?

Affiliations

Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?

Author

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical